1. Biotechnology

Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen

Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis, clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and Ipsen.

Comments to: Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen

Login

Welcome to Life Science News!

"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.